&lt;p&gt;GADD45&amp;alpha;-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status&lt;/p&gt;

Dove Press, OncoTargets and Therapy, (Volume 12), p. 3161-3170, 2019

<p>GADD45&alpha;-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status</p>

Journal article published in 2019 by Qiwen Shi, Vijaykumar Sutariya, Sheeba V. Gupta, Deepak Bhatia

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving forbidden

Postprint: archiving allowed

Upload

Published version: archiving allowed

Upload

Policy details

Data provided by